Los Angeles based Capricor Therapeutics, Inc. CAPR is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases. The Company has six drug candidates in stages of development which includes CAP , CAP , CSps, Exosomes, Cenderitide and CU NP. Capricor s lead product candidate, an allogeneic cardiosphere derived cell CDC product, CAP , aims to attenuate and potentially improve damage to the heart caused by a heart attack and is currently under evaluation in the Phase I/II ALLSTAR clinical trial of patients days to year after a heart attack. Ongoing research at Capricor focuses on in depth product characterization, expanded use of current products, development of next generation products, and identification of new technologies. The company was founded in and is headquartered in Beverly Hills, CA.
Quote | Capricor Therapeutics Inc. (NASDAQ:CAPR)
Last: | $4.81 |
---|---|
Change Percent: | 0.21% |
Open: | $4.82 |
Close: | $4.81 |
High: | $4.85 |
Low: | $4.66 |
Volume: | 478,195 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Capricor Therapeutics Inc. (NASDAQ:CAPR)
2024-07-01 09:37:59 ET More on Capricor Therapeutics Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform Read the full article on Seeking Alpha For fur...
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
Message Board Posts | Capricor Therapeutics Inc. (NASDAQ:CAPR)
Subject | By | Source | When |
---|---|---|---|
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Po | staynafloat | investorshub | 04/27/2023 1:22:47 PM |
Patience will pay off huge soon I am holding | Volcano | investorshub | 04/03/2023 11:00:30 PM |
Capr. If you go back about 2 years | ed3/6me | investorshub | 03/26/2023 9:03:03 PM |
I would say BLA submission this summer Pps will | Volcano | investorshub | 03/18/2023 5:32:30 PM |
This one will run 1000% in the coming | Volcano | investorshub | 03/16/2023 12:32:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...